Gefitinib, a small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has been shown to induce autophagy as well as apoptosis in tumor cells. Yet, how to exploit autophagy and apoptosis to improve therapeutic efficacy of this drug against cancer remains to be explored. We reported here that MK-2206, a potent allosteric Akt inhibitor currently in Phase I trials in patients with solid tumors, could reinforce the cytocidal effect of gefitinib against glioma. We found that co-treatment with gefitinib and MK-2206 increased the cytotoxicity of this growth factor receptor inhibitor in the glioma cells, and the Compusyn synergism/antagonism analysis showed that MK-2206 acted synergistically with gefitinib. The benefit of the combinatorial treatment was also demonstrated in an intracranial glioma mouse model. In the presence of MK-2206, there was a significant increase in apoptosis in glioma cells treated with gefitinib. MK-2206 also augmented the autophagy-inducing effect of gefitinib, as evidenced by increased levels of the autophagy marker, LC3-II. Inhibition of autophagy by silencing of the key autophagy gene, beclin 1 or 3-MA, further increased the cytotoxicity of this combinatorial treatment, suggesting that autophagy induced by these agents plays a cytoprotective role. Notably, at 48 hours following the combinatorial treatment, the level of LC3-II began to decrease but Bim was significantly elevated, suggesting a switch from autophagy to apoptosis. Based on the synergistic effect of MK-2206 on gefitinib observed in this study, the combination of these two drugs may be utilized as a new therapeutic regimen for malignant glioma.
Introduction
Activation of epidermal growth factor receptor (EGFR), a cell surface protein belonging to the ErbB receptor tyrosine kinase family, exerts stimulatory effects on a number of oncogenic signaling cascades such as RAS, phosphoinositide 3-kinase (PI3K), and mitogen-activated protein kinase (MAPK) pathways, thereby promoting proliferation, growth and survival of tumor cells (1) . Based on the essential role of the EGFR-initiated signaling in tumor development and progression, this receptor tyrosine kinase has been actively pursued as a therapeutic target for cancer treatment (2) . Thus far, EGFR inhibitors such as gefitinib, cetuximab, and erlotinib have already been approved as targeted therapies for treating patients with lung cancer, colon cancer, breast cancer, and some other types of malignancies (3) .
Malignant gliomas are the most common and aggressive type of primary brain tumors in humans. Despite optimal treatment with surgery, chemotherapy and radiation therapy, the prognosis of this disease remains poor. Thus, more effective therapeutic interventions are urgently needed in order to improve the treatment of this malignancy. Since mutations or aberrant expression of EGFR is frequent in this type of cancer, use of inhibitors of EGFR is believed to be an effective therapeutic intervention for patients with malignant gliomas (4) (5) .
Indeed, EGFR inhibitors such as lapatinib have been reported to exhibit inhibitory effects on proliferation and migration of glioma cells and to activate apoptosis (6) . Gefitinib (Iressa, ZD1839), another selective inhibitor of EGFR tyrosine kinase, has also been shown to possess inhibitory effects on both cell viability and invasion in maligant gliomas that have amplification of EGFR (7) . In addition, inhibitors of EGFR such as erlotinib and gefitinib have been reported to inhibit proliferation of tumor-initiating cells in human glioma (8) . Nevertheless, in the reported clinical trials, gefitinib only demonstrated modest anti-glioma efficacy (9) . More recently, it was shown that, although gefitinib can reach the brain tumors in high concentrations and efficiently dephosphorylate EGFR, this drug is not sufficient to repress the activity of the pathway (10) . It is likely that single molecular targeted therapy may not be enough to control the complex pathogenesis of glioblastoma, and that targeting multiple signaling molecules of the EGFR-initiated pathways may produce better anti-tumor effects.
The Akt serine/threonine kinase family, which consists of Akt1, Akt2 and Akt3, is a central component of the PI3 kinase pathway, and aberrant activation of Akt is found to be common in malignant glioma (11) (12) . The activity of Akt is closely regulated by the EGFR signaling, and has inhibitory effects on apoptosis. Recently, inhibiting Akt has been shown to possess autophagy-inducing effect in addition to apoptogenic effect (13) , so as do the EGFR inhibitors including gefitinib (14) (15) . Autophagy is a catabolic process that degrades cytoplasmic components via the lysosomal machinery. Induction of autophagy can promote either cell survival or cell death, depending on different circumstances (16) . In light of the critical role of Akt in the EGFR-initiated pathway, we sought to determine whether dual inhibitions of EGFR and Akt by corresponding inhibitors would reinforce the anti-glioma efficacy of EGFR inhibitors, and what roles autophagy would play in determining the anti-tumor efficacy of the combinatorial therapy. It has been reported that the novel small molecule allosteric inhibitor of Akt, MK-2206, which is being tested both in pre-clinical settings and clinical trials as an anticancer agent, can synergistically enhance the antitumor efficacy of some conventional chemotherapeutic drugs and molecular targeted agents in pre-clinical models of lung cancer, ovarian cancer and breast cancer (17) (18) (19) . In this study, we focused on testing whether combining MK-2206 with gefitinib would improve the anti-glioma activity of this EGFR inhibitor, and how induction of autophagy would affect apoptotic cell death caused by 5 dual inhibitions of EGFR and Akt. We found that MK-2206 synergistically enhanced the cytocidal effects of gefitinib on glioma cells, and the mechanism of this synergism involved the Akt inhibition-mediated modulation of apoptosis and autophagy in tumor cells treated with the targeted therapies. The results of the current study recommend that that combined administration of gefitinib and MK-2206 should be considered as a new therapeutic tactic that warrants clinical investigation for treating patients with malignant brain tumors. 
Materials and Methods
Cell lines and culture. The human glioblastoma cell lines, T98G, LN229, and U87MG were purchased from American Type Culture Collection. These glioma cell lines all express EGFR. T98G cells were cultured in Ham's F-10: DMEM (10:1) medium, and LN229, U251 and U87MG cells were cultured in DMEM medium. These media were supplemented with 10% fetal bovine serum, 100 units/mL of penicillin, and 100 µg/mL of streptomycin. Cells were maintained at 37 o C in a humidified atmosphere containing 5% CO 2 /95% air. All cell cultures were monitored routinely and found to be free of contamination by mycoplasma or fungi. All cell lines were discarded after three months and new lines propagated from frozen stocks.
Reagents and antibodies. MK-2206 was a gift from Merck & Co. Inc. Gefitinib was purchased from LC Laboratories.
3-MA, Bafilomycin A1 and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma. Antibodies to LC-3, Akt, Bim, survivin, phospho-mTOR, mTOR, phospho-S6 kinase (Ser371), S6 kinase, phospho-EGFR and EGFR, were purchased from Cell Signaling Technologies. Antibodies to Beclin 1 and α-tubulin were purchased from Santa Cruz. All cell culture media were purchased from Invitrogen.
Western blot reagents were obtained from Pierce Biotechnology.
Apoptosis assay. Apoptosis was determined by flow cytometric analysis of Annexin V and 7-AAD staining. Briefly, 100 µl of Guava Nexin reagent (Millipore) was added to 1 x 10 5 cells (in 100 µl) and the cells were then incubated with the reagent for 20 min at room temperature in the dark. At the end of incubation, the samples were analyzed by a Guava EasyCyte Plus FlowCytometry System (Millipore). Western blot. Cells were lysed in the M-PER mammalian protein extraction reagent (Thermo Scientific) supplemented with a protease inhibitor cocktail (Roche) at room temperature for 5 minutes, followed by centrifugation at 14,000 x g for 10 minutes. Protein concentrations of cell lysates were measured using the Bio-Rad DC assay reagent (Bio-Rad). Proteins (20- Statistical analysis. The differences between treatments were analyzed using a two-sample ttest. The survival curves of the tumor -bearing mice subjected to different treatments were estimated using Kaplan-Meier method and compared by log-rank statistic analysis.
Results

Gefitinib simultaneously induces apoptosis and autophagy in human glioma cells
Apoptosis and autophagy are the two cellular processes likely to alter efficacy of a therapeutic agent. In this study, we observed that treatment of the human glioma cell lines LN229 and T98G with gefitinib, which decreased the phosphorylation of p-EGFR (Fig. 1B) , triggered both apoptosis and autophagy in a dose-dependent manner, as evidenced by increases in the number of cells with Annexin V staining (Fig. 1C) , an indicator of apoptosis, and in the amount of LC3 II (Fig. 1D) , a specific marker of autophagy. We also demonstrated that in the presence of bafilomycin A1 (an inhibitor of lysosomal protease), the accumulation of LC3 II was more abundant, indicating an increase in autophagic flux (Fig. 1D ). Stimulatory effect of low concentration (0.5 µM) but inhibitory effect of high concentrations (1 and 5 µM) of gefitinib on EGFR phosphorylation was also observed by others (20) . Treatment with gefitinib also caused a dose-dependent decrease in the phosphorylation of Akt (Fig. 1E) , which indicates an inhibition of Akt activity. These results imply that activation of apoptosis and autophagy in response to gefitinib treatment could be a part of cellular processes that determine the cytocidal efficacy of this EGFR inhibitor.
The Akt inhibitor, MK-2206, synergistically increases the cytocidal effect of gefitinib on human glioma cells
As gefitinib showed an inhibitory effect on Akt activity (Fig. 1E) , and this action might account, at least in part, for its pro-apoptotic effect, we next tested in LN229, T98G and U87MG human glioma cell lines whether combining an Akt inhibitor with gefitinib would enhance the cytocidal efficacy of this EGFR inhibitor. To delineate the relationship between autophagy and apoptosis activated by gefitinib and MK-2206, we extended our observation of these two cellular processes to 96 h. We found that activation of autophagy by gefitinib, as indicated by the levels of LC3 II, lasted up to 96 h (Fig.   4A) ; by contrast, in the presence of MK-2206, autophagy levels reached a peak at 48 h, but began to decline thereafter (Fig. 4B) . Notably, with the decrease of autophagy (LC3 II) after 48 h, the level of the pro-apoptotic protein Bim was further increased (Fig. 4B) . In contrast, no detectable increase in the Bim level was observed in the cells treated with gefitinib alone (Fig.   4A ). Elevations of Bim in the tumor cells subjected to combinatory treatment were accompanied by increases in apoptotic cell death (Fig. 4C) . The importance of Bim in induction of apoptosis was further demonstrated in the experiments showing that knocked down of Bim by siRNA reduced apoptotic rate in those treated cells (Fig. 4D) . These results suggest that excessive autophagy promoted by MK-2206 may trigger a switch from autophagy to apoptotic cell death.
Suppression of autophagy enhances the efficacy of combined treatment with gefitinib and
MK-2206
As autophagy can play either a pro-survival or pro-death role under various stressful conditions, we next wanted to understand how activation of autophagy affected viability of glioma cells treated with gefitinib alone or with the combination of gefitinib and MK-2206. In these experiments, we first suppressed autophagy by silencing the expression of Beclin 1, a key autophagy-regulatory gene, and then determined the viability of tumor cells subjected to the treatments. Fig. 5C and Fig. 5D ). The effect of autophagy on cytocidal effect of the combinatorial treatment was further verified through use of the autophagy inhibitor, 3-MA (1 mM) ( Supplementary Fig. 1A and Figure 1B) . These results suggest that induction of autophagy serves as a compensatory mechanism in tumor cells in response to the targeted therapies.
Regulation of autophagy in glioma cells co-treated with gefitinib and MK-2206 is mediated via the mTOR-S6 kinase pathway
To explore the signaling pathway involved in the modulation of autophagy by combinatorial treatment with gefitinib and MK-2206, we examined the activities of mTOR and S6 kinase, two components downstream of the EGFR-PI3 kinase-Akt cascade with known roles in the regulation of autophagy in response to cellular stress. As shown in Fig. 5E and Fig. 5F , in comparison to treatment with gefitinib alone, the combinatorial treatment with gefitinib and MK-2206 markedly decreased the levels of phospho-mTOR and phospho-S6 kinase, indicating a deactivation of the mTOR-S6 kinase pathway. Since inhibition of mTOR and S6 kinase is known to induce autophagy, the decreases in the activity of this pathway by dual inhibition of 
Discussion
The EGFR-initiated pathway is considered an attractive therapeutic target in malignant glioma due to its frequent dysregulation in this disease. Thus, small-molecule inhibitors of EGFR tyrosine kinase such as gefitinib are being evaluated as anti-glioma therapies (28). Also, it has been noticed that sensitivity of tumor cells to gefitinib is closely correlated to their dependence on Akt activation for survival and proliferation (29) , and this suggests that inhibiting Akt may serve as an approach to improving the anti-tumor efficacy of EGFR inhibitors. In the current study, we evaluated whether or not combining the novel allosteric Akt inhibitor, MK-2206, with gefitinib could enhance the anti-glioma activity of this targeted therapy. Our results demonstrated that gefitinib in combination with MK-2206 produced a synergistic effect against glioma cells (Fig. 2) and enhanced the antitumor activity in an orthotopic glioma mouse model (Fig. 6) . It was reported that the responsiveness to EGFR inhibitors is associated with the coexpressions of EGFRvIII and functional PTEN in glioma cells (30) , and that downstream inhibition of the PI3K pathway can be combined with EGFR inhibitors to promote responsiveness in patients with PTEN-deficient tumors (31) . Indeed, the synergistic effect The synergism between MK-2206 and gefitinib appears to be associated with the modulation of autophagy and apoptosis in the cells subjected to the combinatory treatment of gefitinib and MK-2206 ( Fig. 3 and Fig. 4 ). Apoptosis and autophagy are the two cellular processes known to affect efficacies of numerous cancer therapeutic agents. To explore the mechanism underlying the synergism between gefitinib and MK-2206 in killing tumor cells, we examined the activity of both apoptosis and autophagy in the glioma cells subjected to combinatorial treatment of the two agents. We observed that gefitinib simultaneously induced apoptosis and autophagy (Fig. 1C and Fig. 1D ), and that in the presence of MK-2206, both of apoptosis and autophagy were increased in the tumor cells treated with gefitinib for 48 h. As autophagy may contribute to either cell survival or cell death, we then assessed the role of autophagy in determining the efficacy of the treatments. We found that suppression of autophagy significantly enhanced the cytocidal activity of the combinatorial treatments, suggesting that induction of autophagy is a compensatory response to therapeutic stress.
Interestingly, 48 h after the co-treatments, autophagic activity began to decrease but apoptosis was further activated (Fig. 4B) , and this shift did not occur in the glioma cells treated with gefitinib alone (Fig. 4A) . Co-treatment of gefitinib with MK-2206 also caused a reduction of anti-apoptotic protein, survivin, but led to an elevation of pro-apoptotic protein, Bim (Fig. 3B) .
It has been reported that Bim is required for apoptosis induced by certain targeted therapy in cancer cells with oncogenic EGFR (34), and that the down-regulation of survivin plays a pivotal role in the gefitinib-induced apoptosis (35). Thus, our results are consistent with those reported observations. More importantly, our study suggests that Akt inhibitors such as MK-2206 may play a therapeutically beneficial role in promoting functional switch from autophagy to apoptosis, and this switch may account for the synergistic effect of MK-2206 on cytocidal activity of gefitinib. Evidence of a switch from autophagy to apoptosis was previously reported for temozolomide (36), a chemotherapeutic drug commonly used in treatment of GBM, and targeting autophagy has been proposed as a new approach to treating apoptosis-resistant GBM (37). Additionally, we found that mTOR-S6K pathway, which locates down-stream of Akt and normally plays a role in suppressing autophagy (38), was involved in the induction of autophagy in the cells co-treated with gefitinib and MK-2206, as evidenced by a decrease in the levels of pmTOR and p-S6K (Fig. 5E and Fig. 5F ). These observations were consistent with our previous increasingly appreciated that manipulating autophagy and apoptosis may achieve better therapeutic outcomes in cancer treatment; hence, the molecular mechanisms and pathways involved in the regulation of the cross-talk between autophagy and apoptosis, and the approaches to exploiting these cellular process for killing cancer cells, are undergoing extensive exploration.
The results reported here demonstrate that the novel allosteric Akt inhibitor, MK-2206, can synergize with gefitinib in inhibiting malignant glioma by promoting a switch from autophagy to apoptosis, suggesting that this dual targeted therapy may make these drugs more useful and 
